Paris‑based clinical software maker Ennov secured fresh capital from private‑equity firms Bregal Sagemount and Ardian. The financing targets accelerated global rollout, AI‑centric product development and broader market reach. Founder‑CEO Olivier Pâris will steer the next growth phase as the deal moves toward a late‑Q2 2026 close.

Board seats will open for Gene Yoon, Curt Witte and Harrison Brunelli of Sagemount, alongside Alexis Saada from Ardian. Their presence signals a hands‑on approach to scaling Ennov’s suite of life‑science and healthcare solutions, a sector where digital adoption has surged post‑pandemic.

Investors are betting on Ennov’s AI capabilities to differentiate its offering amid intense competition from larger EHR vendors. By expanding its go‑to‑market engine, the company hopes to capture a larger share of the $200 billion global health‑tech spend, reinforcing its position with midsize pharma and biotech clients.

Closing the round will boost Ennov’s balance sheet, allowing rapid hiring and product rollout across Europe and North America. The infusion underscores private equity’s appetite for niche health‑tech platforms that combine regulatory expertise with emerging AI tools.